About Prescient Therapeutics

Prescient Therapeutics (ASX:PTX) is a clinical-stage biotechnology company developing innovative gene editing and gene editing-powered T-cell therapies for cancer and other serious diseases. PTX is developing a pipeline of other gene-edited T-cell therapies for the treatment of solid tumours and other blood cancers. The company is also developing a gene editing platform that can be used to develop gene editing therapies for a wide range of diseases.

Snapshot

Public AUOwnership

1986Year founded

11Employees

Melbourne, AustraliaHead office

Loading Map...

Global footprint

Operations

All Locations

Melbourne, AU

Products and/or services of Prescient Therapeutics

OmniCAR: an advanced, universal CAR platform, offering controllable T-cell activity and the ability to target multiple antigens with a single cell product.
CellPryme: an advanced cell therapy enhancement platform designed to boost CAR-T effectiveness. It comprises two distinct components, each effective independently and synergistic when combined.
PTX-100: a pioneering compound that inhibits the cancer growth enzyme GGT-1, disrupting oncogenic Ras pathways and inducing cancer cell apoptosis. It is the sole GGT-1 inhibitor in clinical development globally.
PTX-200: a PH domain inhibitor that effectively blocks the Akt tumour survival pathway crucial in various cancers such as breast, ovarian, and leukaemia. PTX-200 acts specifically on Akt without affecting other kinases.

Prescient Therapeutics executive team

Mr. James McDonnellChief Executive Officer
Ms. Melanie Jaye Leydin B.Bus, C.A.CFO & Company Secretary
Dr. Rebecca TunstallChief Operating Officer
Dr. Marissa Lim M.B.A., MBBSChief Medical Officer